Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability. Its lead product candidates include XMT-1522, an ADC targeting HER2-expressing tumors, which is in Phase I clinical trial for treating patients with breast cancer, non-small-cell-lung-cancer (NSCLC), and gastric cancer; and XMT-1536, an ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, NSCLC, and other cancers. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck KGaA; and Asana BioSciences, LLC. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2002 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRSN
CUSIPN/A
Phone617-498-0020
Debt
Debt-to-Equity RatioN/A
Current Ratio3.80
Quick Ratio3.80
Price-To-Earnings
Trailing P/E Ratio-5.97
Forward P/E Ratio-8.17
P/E GrowthN/A
Sales & Book Value
Annual Sales$17.55 million
Price / Sales25.07
Cash FlowN/A
Price / CashN/A
Book Value$3.08 per share
Price / Book6.24
Profitability
EPS (Most Recent Fiscal Year)($3.22)
Net Income$-38,700,000.00
Net Margins-263.80%
Return on Equity-124.32%
Return on Assets-36.28%
Miscellaneous
Employees78
Outstanding Shares22,900,000
Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions
What is Mersana Therapeutics' stock symbol?
Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."
How were Mersana Therapeutics' earnings last quarter?
Mersana Therapeutics Inc (NASDAQ:MRSN) posted its quarterly earnings data on Monday, May, 14th. The company reported ($0.54) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.61) by $0.07. The business earned $3.06 million during the quarter, compared to the consensus estimate of $3.49 million. Mersana Therapeutics had a negative return on equity of 124.32% and a negative net margin of 263.80%. View Mersana Therapeutics' Earnings History.
What price target have analysts set for MRSN?
6 Wall Street analysts have issued twelve-month price targets for Mersana Therapeutics' stock. Their predictions range from $23.00 to $33.00. On average, they expect Mersana Therapeutics' stock price to reach $26.80 in the next twelve months. View Analyst Ratings for Mersana Therapeutics.
Who are some of Mersana Therapeutics' key competitors?
Some companies that are related to Mersana Therapeutics include Deciphera Pharmaceuticals (DCPH), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Zogenix (ZGNX), Myovant Sciences (MYOV), G1 Therapeutics (GTHX), Mallinckrodt (MNK), Aimmune Therapeutics (AIMT), Biohaven Pharmaceutical (BHVN), Cambrex (CBM), ImmunoGen (IMGN), TherapeuticsMD (TXMD), Mirati Therapeutics (MRTX), ARMO Biosciences (ARMO) and Innoviva (INVA).
Who are Mersana Therapeutics' key executives?
Mersana Therapeutics' management team includes the folowing people:
- Mr. David M. Mott, Exec. Chairman (Age 53)
- Ms. Anna Protopapas, Pres, CEO & Director (Age 54)
- Dr. Timothy B. Lowinger Ph.D., Sr. VP & Chief Scientific Officer (Age 54)
- Dr. Donald A. Bergstrom, Former Sr. VP & Chief Medical Officer (Age 46)
- Mr. Mikhail Papisov Ph.D., Co-Founder
When did Mersana Therapeutics IPO?
(MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Has Mersana Therapeutics been receiving favorable news coverage?
News stories about MRSN stock have trended somewhat positive on Sunday, Accern reports. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mersana Therapeutics earned a media sentiment score of 0.07 on Accern's scale. They also gave media coverage about the company an impact score of 46.21 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Mersana Therapeutics' major shareholders?
Mersana Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Rock Springs Capital Management LP (5.69%), BlackRock Inc. (3.58%), RHO Capital Partners Inc. (3.49%), JPMorgan Chase & Co. (1.35%), Point72 Asset Management L.P. (0.74%) and Northern Trust Corp (0.49%). View Institutional Ownership Trends for Mersana Therapeutics.
Which major investors are selling Mersana Therapeutics stock?
MRSN stock was sold by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, JPMorgan Chase & Co., RHO Capital Partners Inc., Allianz Asset Management GmbH, Allianz Asset Management GmbH and DekaBank Deutsche Girozentrale. View Insider Buying and Selling for Mersana Therapeutics.
Which major investors are buying Mersana Therapeutics stock?
MRSN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., Northern Trust Corp, Russell Investments Group Ltd., Candriam Luxembourg S.C.A., Schwab Charles Investment Management Inc., Stanley Laman Group Ltd. and Quantitative Systematic Strategies LLC. View Insider Buying and Selling for Mersana Therapeutics.
How do I buy shares of Mersana Therapeutics?
Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mersana Therapeutics' stock price today?
One share of MRSN stock can currently be purchased for approximately $19.21.
How big of a company is Mersana Therapeutics?
Mersana Therapeutics has a market capitalization of $427.12 million and generates $17.55 million in revenue each year. The company earns $-38,700,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Mersana Therapeutics employs 78 workers across the globe.
How can I contact Mersana Therapeutics?
Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]
MarketBeat Community Rating for Mersana Therapeutics (MRSN)
MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote "Outperform" if you believe MRSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days.
